| 68.28 1.23 (1.83%) | 07-17 15:45 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 90.2 | 1-year : | 105.35 |
| Resists | First : | 77.23 | Second : | 90.2 |
| Pivot price | 69.09  |
|||
| Supports | First : | 64.41 |
Second : | 56.49 |
| MAs | MA(5) : | 67.77  |
MA(20) : | 67.83 |
| MA(100) : | 72.2 |
MA(250) : | 56.91 |
|
| MACD | MACD : | 0.7 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 40.8 |
D(3) : | 40.5 |
| RSI | RSI(14): 50.8 |
|||
| 52-week | High : | 109 | Low : | 21.02 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ NKTR ] has closed above bottom band by 41.9%. Bollinger Bands are 30.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 69.2 - 69.58 | 69.58 - 69.89 |
| Low: | 64.67 - 65.2 | 65.2 - 65.63 |
| Close: | 66.26 - 67.06 | 67.06 - 67.71 |
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
Thu, 16 Jul 2026
Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Gr - The National Law Review
Tue, 14 Jul 2026
BTIG Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $178 - Moomoo
Fri, 10 Jul 2026
NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results - Stocktwits
Mon, 06 Jul 2026
Nektar Therapeutics (NKTR) Advances Autoimmune Pipeline, Is The Upside Already Priced In? - simplywall.st
Fri, 05 Jun 2026
What Makes Nektar Therapeutics (NKTR) a Promising Mid-Cap Healthcare Stock - Yahoo Finance
Wed, 03 Jun 2026
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 34 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 80.3 (%) |
| Shares Short | 6,900 (K) |
| Shares Short P.Month | 4,610 (K) |
| EPS | -7.66 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 19.54 |
| Profit Margin | -284.2 % |
| Operating Margin | -352.3 % |
| Return on Assets (ttm) | -15.3 % |
| Return on Equity (ttm) | -53.6 % |
| Qtrly Rev. Growth | 3.7 % |
| Gross Profit (p.s.) | 1.64 |
| Sales Per Share | 1.64 |
| EBITDA (p.s.) | -3.67 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -204 (M) |
| Levered Free Cash Flow | -107 (M) |
| PE Ratio | -8.89 |
| PEG Ratio | 0.3 |
| Price to Book value | 3.48 |
| Price to Sales | 41.34 |
| Price to Cash Flow | -11.29 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|